Sensitizing effect of galectin-7 in urothelial cancer to cisplatin through the accumulation of intracellular reactive oxygen species

Cancer Research

Volumn 67, Issue 3, 2007, Pages 1212-1220

  Matsui, Yoshiyuki ^a   Ueda, Shugo ^b   Watanabe, Jun ^a   Kuwabara, Ichiro ^c   Ogawa, Osamu ^a   Nishiyama, Hiroyuki ^a  

^a KYOTO UNIVERSITY   (Japan)

^b Kitano Hospital   (Japan)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CISPLATIN; EPIRUBICIN; GALECTIN 7; METHOTREXATE; PROTEIN BAX; PROTEIN P53; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE;

ARTICLE; BLADDER CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; SENSITIZATION; UROGENITAL TRACT CANCER; UROTHELIAL CANCER;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TUMOR; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; GALECTINS; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; REACTIVE OXYGEN SPECIES; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 33847009130     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-3283     Document Type: Article

References (47)

1. Raghavan D, Shipley WU, Garnick MB, et al. Biology and management of bladder cancer. N Engl J Med 1990;322:1129-38.
2. Giuliani L, Giberti C, Martorana G, et al. Results of radical cystectomy for primary bladder cancer. Retrospective study of more than 200 cases. Urology 1985;26:243-8.
3. Pagano F, Bassi P, Galetti TP, et al. Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes, and metastases classification. J Urol 1991;145:45-50.
4. Collaboration ABCM-a. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 2003;361:1927-34.
5. Hussain SA, James ND. The systemic treatment of advanced and metastatic bladder cancer. Lancet Oncol 2003;4:489-97.
6. Hollstein M, Sidransky D, Vogelstein B, et al. p53 mutations in human cancers. Science 1991;253:49-53.
7. McKnight JJ, Gray SB, O'Kane HF, et al. Apoptosis and chemotherapy for bladder cancer. J Urol 2005;173:683-90.
8. Cordon-Cardo C, Dalbagni G, Saez GT, et al. p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int J Cancer 1994;56:347-53.
9. Esrig D, Sprack CH III, Nichols PW, et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 1993;143:1389-97.
10. Sarkis AS, Bajorin DF, Reuter VE, et al. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol 1995;13:1384-90.
11. Cote RJ, Esrig D, Groshen S, et al. p53 and treatment of bladder cancer. Nature 1997;385:123-5.
12. Watanabe J, Nishiyama H, Matsui Y, et al. Dicoumarol potentiates cisplatin-induced apoptosis mediated by c-Jun N-terminal kinase in p53 wild-type urogenital cancer cell lines. Oncogene 2006;25:2500-8.
13. Polyak K, Xia Y, Zweier JL, et al. A model for p53-induced apoptosis. Nature 1997;389:300-5.
14. Liu FT, Rabinovich GA. Galectins as modulators of tumour progression. Nat Rev Cancer 2005;5:29-41.
15. Hernandez JD, Baum LG. Ah, sweet mystery of death! Galectins and control of cell fate. Glycobiology 2002;12:127-36R.
16. Rabinovich GA. Galectins: an evolutionarily conserved family of animal lectins with multifunctional properties; a trip from the gene to clinical therapy. Cell Death Differ 1999;6:711-21.
17. Liu FT. Galectins: a new family of regulators of inflammation. Clin Immunol 2000;97:79-88.
18. Liu FT, Patterson RJ, Wang JL. Intracellular functions of galectins. Biochim Biophys Acta 2002;1572:263-73.
19. Magnaldo T, Fowlis D, Darmon M. Galectin-7, a marker of all types of stratified epithelia. Differentiation 1998;63:159-68.
20. Kuwabara I, Kuwabara Y, Yang RY, et al. Galectin-7 (PIG1) exhibits pro-apoptotic function through JNK activation and mitochondrial cytochrome c release. J Biol Chem 2002;277:3487-97.
21. Ueda S, Kuwabara I, Liu FT. Suppression of tumor growth by galectin-7 gene transfer. Cancer Res 2004;64:5672-6.
22. Watanabe J, Nishiyama H, Okubo K, et al. Clinical evaluation of p53 mutations in urothelial carcinoma by IHC and FASAY. Urology 2004;63:989-93.
23. Sobin LH, Fleming ID; Union Internationale Contre le Cancer and the American Joint Committee on Cancer. TNM classification of malignant tumors, fifth edition (1997). Cancer 1997;80:1803-4.
24. Southgate J, Hutton KA, Thomas DF, et al. Normal human urothelial cells In vitro: proliferation and induction of stratification. Lab Invest 1994;71:583-94.
25. Inoue T, Nakanishi H, Inada K, et al. Real time reverse transcriptase polymerase chain reaction of urinary cytokeratin 20 detects transitional cell carcinoma cells. J Urol 2001;166:2134-41.
26. Sasada T, Iwata S, Sato N, et al. Redox control of resistance to cis-diamminedichloroplatinum (II) (CDDP): protective effect of human thioredoxin against CDDP-induced cytotoxicity. J Clin Invest 1996;97:2268-76.
27. Hsu YT, Youle RJ. Nonionic detergents induce dimerization among members of the Bcl-2 family. J Biol Chem 1997;272:13829-34.
28. Kim M, Jung SO, Park K, et al. Detection of Bax protein conformational change using a surface plasmon resonance imaging-based antibody chip. Biochem Biophys Res Commun 2005;338:1834-8.
29. Lei K, Davis RJ. JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis. Proc Natl Acad Sci U S A 2003;100:2432-7.
30. Tsuruta F, Sunayama J, Mori Y, et al. JNK promotes Bax translocation to mitochondria through phosphorylation of 14-3-3 proteins. EMBO J 2004;23:1889-99.
31. Benhar M, Dalyot I, Engelberg D, et al. Enhanced ROS production in oncogenically transformed cells potentiates c-Jun N-terminal kinase and p38 mitogen-activated protein kinase activation and sensitization to genotoxic stress. Mol Cell Biol 2001;21:6913-26.
32. Zhang Y, Chen F. Reactive oxygen species (ROS), troublemakers between nuclear factor-κB (NF-κB) and c-Jun NH(2)-terminal kinase (JNK). Cancer Res 2004;64:1902-5.
33. Kopitz J, Andre S, von Reitzenstein C, et al. Homodimeric galectin-7 (p53-induced gene 1) is a negative growth regulator for human neuroblastoma cells. Oncogene 2003;22:6277-88.
34. Demers M, Magnaldo T, St-Pierre Y. A novel function for galectin-7: promoting tumorigenesis by up-regulating MMP-9 gene expression. Cancer Res 2005;65:5205-10.
35. Bernerd F, Sarasin A, Magnaldo T. Galectin-7 overexpression is associated with the apoptotic process in UVB-induced sunburn keratinocytes. Proc Natl Acad Sci U S A 1999;96:11329-34.
36. Derijard B, Hibi M, Wu IH, et al. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 1994;76:1025-37.
37. Sluss HK, Barrett T, Derijard B, et al. Signal transduction by tumor necrosis factor mediated by JNK protein kinases. Mol Cell Biol 1994;14:8376-84.
38. Mansouri A, Ridgway LD, Korapati AL, et al. Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and , cell death in ovarian carcinoma cells. J Biol Chem 2003;278:19245-56.
39. Basu S, Kolesnick R Stress signals for apoptosis: ceramide and c-Jun kinase. Oncogene 1998;17:3277-85.
40. Vasilevskaya IA, Rakitina TV, O'Dwyer PJ. Quantitative effects on c-Jun N-terminal protein kinase signaling determine synergistic interaction of cisplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines. Mol Pharmacol 2004;65:235-43.
41. Hsu YT, Wolter KG, Youle RJ. Cytosol-to-membrane redistribution of Bax and Bcl-X(L) during apoptosis. Proc Natl Acad Sci U S A 1997;94:3668-72.
42. Duggan BJ, Maxwell P, Kelly JD, et al. The effect of antisense Bcl-2 oligonucleotides on Bcl-2 protein expression and apoptosis in human bladder transitional cell carcinoma. J Urol 2001;166:1098-105.
43. Horiguchi Y, Kuroda K, Nakashima I, et al. Antitumor effect of a novel nuclear factor-κB activation inhibitor in bladder cancer cells. Expert Rev Anticancer Ther 2003;3:793-8.
44. Tanaka M, Grossman HB. In vivo gene therapy of human bladder cancer with PTEN suppresses tumor growth, downregulates phosphorylated Akt, and increases sensitivity to doxorubicin. Gene Ther 2003;10:1636-42.
45. Arner ES, Nakamura H, Sasada T, et al. Analysis of the inhibition of mammalian thioredoxin, thioredoxin reductase, and glutaredoxin by cis-diamminedichloroplatinum (II) and its major metabolite, the glutathione-platinum complex. Free Radic Biol Med 2001;31:1170-8.
46. Nguyen P, Awwad RT, Smart DD, et al. Thioredoxin reductase as a novel molecular target for cancer therapy. Cancer Lett 2006;236:164-74.
47. Takata R, Katagiri T, Kanehira M, et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res 2005;11:2625-36.